Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545786 | 0.87 | DRD3 (0.46) | SLC6A2SLC6A3SLC6A4USP30GRIA4 | |
| SCHEMBL26284685 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL24877823 | 0.81 | DRD2 (0.44) | USP30DRD2DRD3MC4R | |
| SCHEMBL25004304 | 0.79 | HRH3 (0.44) | MC4RESRRG | |
| SCHEMBL22667366 | 0.79 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4USP30HTR2A | |
| SCHEMBL26284861 | 0.77 | DRD3 (0.46) | SLC6A2SLC6A3SLC6A4GRIA4DRD2 | |
| SCHEMBL23978589 | 0.76 | SRD5A1 (0.45) | DRD2MC4RESRRG | |
| SCHEMBL13698248 | 0.74 | DRD2 (0.44) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL14136276 | 0.74 | DRD2 (0.44) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL13698216 | 0.73 | DRD2 (0.43) | SLC6A2SLC6A3SLC6A4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265071-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. | 2023-08-24 | — | — | US | disclosed |
| WO-2023283425-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265071-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | CRBN, IKZF1, IKZF3 | SLC6A2 4638/4885SLC6A3 4282/4885SLC6A4 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.